Takeda presents real-world data supporting efficacy of Entyvio in IBD

Japanese drugmaker Takeda Pharmaceutical (TSE: 4502) has presented eight real-world analyses into Entyvio (vedolizumab) for the treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease.

Ulcerative colitis and Crohn’s disease are two of the most common forms of inflammatory bowel disease. Both are chronic, relapsing, remitting, inflammatory conditions of the gastrointestinal tract that are often progressive in nature.

Entyvio is approved by the US Food and Drug Administration for use by adults with these conditions.